We first evaluated the efficacy of SAH5-EJ1 compared to Sapitinib in lung adenocarcinoma cell lines representing wildtype HER1 (A549) and the HER1 T790M mutation (H1975) [36, 37]. Here, EGFR is linked to lung adenocarcinoma.